Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. This short discussion reviews the path to approval, the importance of the first approval for an oral short-course treatment option, and the future holds for this drug.
To learn more about current and future treatment options for MS patients,click here.
Facebook Comments